Charles River Laboratories International, Inc. $CRL Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 25.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 62,084 shares of the medical research company’s stock after selling 20,876 shares during the period. Hsbc Holdings PLC owned 0.13% of Charles River Laboratories International worth $12,401,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter worth $26,000. Los Angeles Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $42,000. Sfam LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $43,000. Geneos Wealth Management Inc. lifted its position in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the last quarter. Finally, Activest Wealth Management boosted its holdings in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on CRL. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Mizuho set a $192.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Finally, CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their price objective for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Charles River Laboratories International Stock Performance

CRL opened at $212.66 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The business’s 50 day moving average is $176.29 and its 200-day moving average is $183.13. The stock has a market cap of $10.24 billion, a PE ratio of -56.56, a price-to-earnings-growth ratio of 2.31 and a beta of 1.46. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.